Objective The predictive value of N-terminal pro-brain natriuretic peptide(NT-proBNP) in patients with stable coronary artery disease(SCAD) in the drug-eluting stent era is not yet clear. We aimed to evaluate the prog...Objective The predictive value of N-terminal pro-brain natriuretic peptide(NT-proBNP) in patients with stable coronary artery disease(SCAD) in the drug-eluting stent era is not yet clear. We aimed to evaluate the prognostic value of NT-proBNP in SCAD patients after percutaneous coronary intervention(PCI). Methods We examined 4,293 consecutive SCAD patients who underwent PCI between January 2013 and December 2013 in Fuwai Hospital, China. The primary endpoint was all-cause death. NT-proBNP levels were measured before PCI using Elisa kits(Biomedica, Austria). The indication for PCI was based on the degree of coronary stenosis and evidence of ischemia. Results Among 3,187 SCAD patients with NT-proBNP data, after a 2-year follow-up, NT-proBNP levels were predictive for all-cause death in the SCAD population [area under the receiver operating characteristic curve, 0.768; 95% confidence interval(CI), 0.687-0.849; P < 0.001]. At the optimum cutoff point of 732 pg/mL, the sensitivity and specificity of death was 75.0% and 72.3%, respectively. In a multivariable Cox regression model, the death hazard ratio was 6.43(95% CI, 2.99-13.82; P < 0.001) for patients with NT-proBNP levels ≥ 732 pg/mL, compared with < 732 pg/mL. Conclusion NT-proBNP is a strong predictor of 2-year death with SCAD after PCI in the drug-eluting stent era.展开更多
由于医疗技术水平的发展,稳定型冠心病的治疗方案在不断地更新与变化。以往,经皮冠状动脉介入术被广泛应用到稳定型冠心病的治疗上。但最近的COURAGE试验(the clinical outcomes utilizing revascularization and aggressive drug evalu...由于医疗技术水平的发展,稳定型冠心病的治疗方案在不断地更新与变化。以往,经皮冠状动脉介入术被广泛应用到稳定型冠心病的治疗上。但最近的COURAGE试验(the clinical outcomes utilizing revascularization and aggressive drug evaluation trial)使得这一治疗手段的合理性和必要性被质疑。我们必须重新考虑稳定型冠心病治疗方案的临床抉择。展开更多
基金funded by The National Key Research and Development Program of China [No.2016YFC1301300 and No.2016YFC1301301]
文摘Objective The predictive value of N-terminal pro-brain natriuretic peptide(NT-proBNP) in patients with stable coronary artery disease(SCAD) in the drug-eluting stent era is not yet clear. We aimed to evaluate the prognostic value of NT-proBNP in SCAD patients after percutaneous coronary intervention(PCI). Methods We examined 4,293 consecutive SCAD patients who underwent PCI between January 2013 and December 2013 in Fuwai Hospital, China. The primary endpoint was all-cause death. NT-proBNP levels were measured before PCI using Elisa kits(Biomedica, Austria). The indication for PCI was based on the degree of coronary stenosis and evidence of ischemia. Results Among 3,187 SCAD patients with NT-proBNP data, after a 2-year follow-up, NT-proBNP levels were predictive for all-cause death in the SCAD population [area under the receiver operating characteristic curve, 0.768; 95% confidence interval(CI), 0.687-0.849; P < 0.001]. At the optimum cutoff point of 732 pg/mL, the sensitivity and specificity of death was 75.0% and 72.3%, respectively. In a multivariable Cox regression model, the death hazard ratio was 6.43(95% CI, 2.99-13.82; P < 0.001) for patients with NT-proBNP levels ≥ 732 pg/mL, compared with < 732 pg/mL. Conclusion NT-proBNP is a strong predictor of 2-year death with SCAD after PCI in the drug-eluting stent era.
文摘由于医疗技术水平的发展,稳定型冠心病的治疗方案在不断地更新与变化。以往,经皮冠状动脉介入术被广泛应用到稳定型冠心病的治疗上。但最近的COURAGE试验(the clinical outcomes utilizing revascularization and aggressive drug evaluation trial)使得这一治疗手段的合理性和必要性被质疑。我们必须重新考虑稳定型冠心病治疗方案的临床抉择。
